Publication

Avelumab versus standard second-line treatment chemotherapy in metastatic colorectal cancer (mCRC) patients with microsatellite instability (MSI): The SAMCO-PRODIGE 54 randomised phase II trial

ANNÉE

2022

AUTEURS

Taieb J, Bouche O, André T, Barbier E, Laurent-Puig P, Bez J, Toullec C, Borg C, Randrian V, Evesque L, Corbinais S, Buecher B, H. Perrier H, Di Fiore F, Gallois C, Lepage C, El Hajbi F, Tougeron D

CONGRÈS/REVUE

ESMO

Etude

PRODIGE 54-FFCD-1603 SAMCO

Localisation

Cancer Colorectal Métastatique

LIEN PUBLICATIONS ASSOCIÉES

https://oncologypro.esmo.org/meeting-resources/esmo-congress/avelumab-versus-standard-second-line-treatment-chemotherapy-in-metastatic-colorectal-cancer-mcrc-patients-with-microsatellite-instability-msi

Lichenoid eruption during antiPD-L1 immunotherapy with avelumab in metastatic colorectal cancer

ANNÉE

2022

AUTEURS

Brayer M, Lepage C, Taieb J, Tougeron D

CONGRÈS/REVUE

Clin Res Hepatol Gastroenterol

Etude

PRODIGE 54-FFCD-1603 SAMCO

Localisation

Cancer Colorectal Métastatique

LIEN PUBLICATIONS ASSOCIÉES

https://doi.org/10.1016/j.clinre.2022.101924

Flexible modeling of longitudinal health-related quality of life data accounting for informative dropout in a cancer clinical trial

ANNÉE

2022

AUTEURS

Winter A, Cuer B, Conroy T, Juzyna B, Gourgou S, Mollevi C, Touraine C

CONGRÈS/REVUE

Qual Life Res

Etude

PRODIGE 5-UNICANCER-ACCORD17/0707

Localisation

Cancer de l’Œsophage et de l’Estomac

LIEN PUBLICATIONS ASSOCIÉES

https://doi.org/10.1007/s11136-022-03252-6

Joint modelling with competing risks of dropout for longitudinal analysis of health-related quality of life in cancer clinical trials

ANNÉE

2022

AUTEURS

Cuer B, Conroy T, Juzyna B, Gourgou S, Mollevi C, Touraine C

CONGRÈS/REVUE

Qual Life Res

Etude

PRODIGE 5-UNICANCER-ACCORD17/0707

Localisation

Cancer de l’Œsophage et de l’Estomac

LIEN PUBLICATIONS ASSOCIÉES

https://doi.org/10.1007/s11136-021-03040-8

Phase III randomized trial comparing systemic versus intra-arterial oxaliplatin, combined with LV5FU2 +/- irinotecan and a targeted therapy, in the first-line treatment of metastatic colorectal cancer restricted to the liver (OSCAR): PRODIGE 49

ANNÉE

2022

AUTEURS

Pernot S, Pellerin O, Mineur L, Monterymard C, Smith D, Lapuyade B, Gallois C, Khemissa Akouz F, De Baere T, Tougeron D, Thirot-Bidault A, Audemar F, Simon M, Lecaille C, Louafi S, Lepage C, Ducreux M, Taieb J

CONGRÈS/REVUE

Dig Liver Dis

Etude

PRODIGE 49-FFCD-1501 OSCAR

Localisation

Cancer Colorectal Métastatique

LIEN PUBLICATIONS ASSOCIÉES

https://doi.org/10.1016/j.dld.2021.12.012

Bevacizumab (B) plus FOLFIRI after failure of platinum-etoposide in patients (pts) with advanced neuroendocrine carcinoma (NEC): The PRODIGE 41-BEVANEC randomized phase II study

ANNÉE

2022

AUTEURS

Walter T, Lievre A, Coriat R, Malka D, El Hajbi F, Di Fiore F, Hentic-Dhome O, Smith D, Hautefeuille V, Roquin G, perrier M, Dahan L, Granger V, Sobhani I, Mineur L, NICCOLI P, Assenat E, Le Malicot K, Lepage C, Lombard Bohas C

CONGRÈS/REVUE

ESMO

Etude

PRODIGE 41-FFCD-BEVANEC

Localisation

Néoplasie Neuroendocrine

LIEN PUBLICATIONS ASSOCIÉES

https://oncologypro.esmo.org/meeting-resources/esmo-congress/bevacizumab-b-plus-folfiri-after-failure-of-platinum-etoposide-in-patients-pts-with-advanced-neuroendocrine-carcinoma-nec-the-prodige-41-bev

STRATEGIC-1: Multi-line therapy trial in unresectable wild-type KRAS/NRAS/BRAF metastatic colorectal cancer A GERCOR-PRODIGE randomized open-label phase III study.

ANNÉE

2022

AUTEURS

Chibaudel B, Dourthe L-M, Andre T, Henriques J, Bourgeois V, Etienne P-L, Desrame J, Carola E, Dupuis O, Baba-Hamed N, Auby D, Louvet C, Maillard E, Romano O, Tournigand C, Garcia-Larnicol ML, Shacham Shmueli E, Healey Bird B, Ghiringhelli F, De Gramont A

CONGRÈS/REVUE

ASCO

Etude

PRODIGE 39-GERCOR-STRATEGIC

Localisation

Cancer Colorectal Métastatique

LIEN PUBLICATIONS ASSOCIÉES

https://ascopubs.org/doi/abs/10.1200/JCO.2022.40.16_suppl.3504

Impact of age on treatment strategies in RAS/BRAF wild-type metastatic colorectal cancer (mCRC): A prespecified subgroup analysis of the GERCOR-PRODIGE STRATEGIC-1 phase III study

ANNÉE

2022

AUTEURS

Carola E, Chibaudel B, Boulahssass R, Dourthe LM, André T, Henriques J, Bourgeois V, Etienne P, Desrame J, Dupuis O, Baba-Hamed N, Auby D, Louvet C, Maillard E, Tournigand C, Garcia-Larnicol ML, Shacham Shmueli E, Bird BH, Ghiringhelli F, De Gramont A

CONGRÈS/REVUE

ESMO

Etude

PRODIGE 39-GERCOR-STRATEGIC

Localisation

Cancer Colorectal Métastatique

LIEN PUBLICATIONS ASSOCIÉES

https://oncologypro.esmo.org/meeting-resources/esmo-congress/impact-of-age-on-treatment-strategies-in-ras-braf-wild-type-metastatic-colorectal-cancer-mcrc-a-prespecified-subgroup-analysis-of-the-gercor-pro

Modified FOLFIRINOX Versus CISGEM Chemotherapy for Patients With Advanced Biliary Tract Cancer (PRODIGE 38 AMEBICA): A Randomized Phase II Study

ANNÉE

2022

AUTEURS

Phelip JM, Desrame J, Edeline J, Barbier E, Terrebonne E, Michel P, Perrier H, Dahan L, Bourgeois V, Akouz FK, Soularue E, Ly VL, Molin Y, Lecomte T, Ghiringhelli F, Coriat R, Louafi S, Neuzillet C, Manfredi S, Malka D, PRODIGE 38 AMEBICA Investigators/Collaborators

CONGRÈS/REVUE

J Clin Oncol

Etude

PRODIGE 38-FFCD-1407 AMEBICA

Localisation

Cancer des Voies biliaires

LIEN PUBLICATIONS ASSOCIÉES

https://doi.org/10.1200/jco.21.00679

Preliminary tolerance analysis of adjuvant chemotherapy in older patients after resection of stage III colon cancer from the PRODIGE 34-FFCD randomized trial

ANNÉE

2022

AUTEURS

Aparicio T, Bouché O, Etienne PL, Barbier E, Mineur L, Desgrippes R, Guérin-Meyer V, Hocine F, Martin J, Le Brun-Ly V, Cretin J, Desramé J, Rinaldi Y, Cany L, Falandry C, Lefevre LB, Marous M, Terrebonne E, Mosser L, Turpin J, Turpin A, Bauguion L, Reichling C, Van den Eynde M, Carola E, Hiret S

CONGRÈS/REVUE

Dig Liver Dis

Etude

PRODIGE 34-FFCD-1402 ADAGE

Localisation

Cancer Colorectal Métastatique

LIEN PUBLICATIONS ASSOCIÉES

https://doi.org/10.1016/j.dld.2022.08.036